学位：博士
职称：讲师、师资博士后

籍贯：安徽宿州市
E-mail：lingwang@scut.edu.cn

个人简介：
王领，男，中共党员，2014年获中山大学药物化学博士学位。2014.08至今，华南理工大学生物科学与工程学院青年教师、师资博士后。近五年来一直从事新药开发基础和应用研究，包括 (1) 药物分子设计方法学研究及其应用（如诱导体系药物设计方法、优势药效片段药物设计方法、机器学习药物设计方法等）；(2) 基于mTOR和CDK激酶靶向抗癌药物分子设计、合成、生物学筛选及分子机制；(3)大数据驱动的药物活性网络预测平台构建及开发(如mTOR Predictor预测系统开发，http://rcdd.sysu.edu.cn/mtor/)；(4) 蛋白质结构改造、功能优化及生物大分子功能模拟(如半乳糖酶催化位点功能改造)。在同行评议主流期刊（如Journal of ChemicalInformation and Modeling,Antimicrobial Agents and Chemotherapy, MedicinalChemistry Communications, Scientific Reports, BBA-General Subjects, Plos one,Molecular Diversity, STEROIDS）发表文章17篇。申请新药相关发明专利三项，授权两项。担任New Journal of Chemistry和Journal of Molecular Modeling杂志审稿人。

研究方向：药物分子设计、药物化学、计算化学生物学

从事以化学、生物、药学、计算机科学为基础的药物分子设计新兴交叉领域，结合实验学科（干湿结合）应用于：
(1)靶向抗癌和降血脂药物的设计合成及活性研究；
(2) 药物重定向研究；
(3)基于氢氘交换质谱和蛋白模拟的药物蛋白相互作用研究；
(4) 网络药理学平台与ADMET预测系统开发。

主持科研项目：
1. 中央高校基本科研业务费面上项目：基于优势药效片段组装的新型mTOR抑制剂设计合成及活性研究；

2. 青年教师科研启动项目：基于配体-靶标网络的降血脂药物预测平台建设；
3. 博士后面上项目：基于优势片段组装的新型mTOR抑制剂发现与活性研究

发表论文：
Publications (^#Co-firstauthor):

1. LingWang, Xiu Le, Long Li, YingchenJu,Zhongxiang Lin, QiongGu and Jun Xu. Discovering New Agents Active againstMethicillin-resistant Staphylococcus aureus with Ligand-based Approaches.J. Chem. Inf. Model.2014, 54 (11),3186–3197.

2. Ling Wang, Qiong Gu, Xuehua Zheng, Jiming Ye, ZhihongLiu, Jiabo Li, Xiaopeng Hu, Arnold T. Hagler, and Jun Xu. Discovery of NewSelective Human Aldose Reductase Inhibitors through Virtual Screening MultipleBinding Pocket Conformation. J. Chem. Inf.Model. 2013, 53, 2409-2422.

3. LingWang, Lei Chen, Zhihong Liu, Minghao Zheng,QiongGu and Jun Xu. Predicting mTOR Inhibitors with a ClassifierUsing Recursive Partitioning and Naïve Bayesian Approaches. Plos One 2014, 9(5): e95221.

4. Ling Wang, Lei Chen, Miao Yu, Li-Hui Xu, Bao Cheng, Yong-Sheng Lin, QiongGu,Xian-Hui He and Jun Xu. Discovering new mTOR inhibitors for cancer treatmentthrough virtual screening methods and in vitro assays. Scientific Reports,2015 (Minor revision).

5. Wei Zhang^#, Ling Wang^#, LipingZhang, WenLi Chen, Xinying Chen, MinyuXie, Guangmei Yan, Xiaopeng Hu, Jun Xu,Jingxia Zhang. Synthesis and biologicalevaluation of steroidal derivatives as selective inhibitors ofAKR1B10. STEROIDS 2014, 86, 39-44. (Co-first author)

6. Bo Xu^#, Ling Wang^#, Lorenzo González-Molleda^#, Yan Wang, Jun Xu andYan Yuan. Antiviral Activity of (+)-Rutamarin against KSHV by InhibitingCatalytic Activity of Human Topoisomerase II. Antimicrob. Agents.Chemother. 2014, 58, 563-573. (Co-first author)

7. Yingying Cao^#, Ling Wang^#, ZhongxiangLin, Fengyin Liang, Zhong Pei, Jun Xu and QiongGu.Dehydroabietylamine derivatives asmultifunctional agents for the treatment of Alzheimer's disease. Med. Chem. Commun. 2014, 5, 1736-1743.(Co-first author)

8. Yi-NingDong^#, Ling Wang^#, Qiong Gu, Haiqin Chen,Xiaoming Liu, Yuanda Song, Wei Chen, Arnold T. Hagler, Hao Zhang, and Jun Xu. OptimizingLactose Hydrolysis by Computer-guided Modification of the Catalytic Site of aWild-type Enzyme, MolecularDiversity 2013, 17, 371-382. (Co-first author)

9. Lei Chen, Ling Wang, QiongGu and Jun Xu. An insilico protocol for identifying mTOR inhibitors from natural products. Molecular Diversity 2014, 18, 841-852.

10. YaliLi, Ling Wang, Zhihong Liu,Chanjuan Li, Jiake Xu, QiongGu, Jun Xu. PredictingSelective Liver X Receptor β AgonistsUsing Multiple Machine Learning Methods. Mol. BioSyst. 2015, 11(5):1241-50.

11. Ying Ying Cao, Ling Wang, Hu Ge, Xi Lin Lu, Zhong Pei, QiongGu, Jun Xu.SalvianolicAcid A, a PolyphenolicAerivative from Salvia miltiorrhiza Bunge, as aMultifunctional Agent for the Treatment of Alzheimer's Disease, Molecular Diversity 2013, 17, 515-524.

12. Jinggong Liu, Jun Qiu, Mingxue Wang, Ling Wang, Lijuan Su, Jinbo Gao,Jun Xu, Shi-Liang Huang, Lian-QuanGu, Zhi-Shu Huang,Ding Li. Synthesisand Characterization of 1H-Phenanthro [9,10-d]imidazole Derivatives asMultifunctional Agents for Treatment of Alzheimer's Disease. Biochim. Biophys. Acta. 2014, 10, 2886-2903.

13. Jun Xu, QiongGu, Haibo Liu, Jaiju Zhou,Xianzhang Bu, Zhishu Huang, Gui Lu, Ding Li, Dongqing Wei, Ling Wang, and LianquanGu. Chemomics and Drug Innovation, SCIENCE CHINA Chemistry2013, 56, 71-85.

14. Xiaoyong Wei, Dan Chen, Yanchun Yi, HuiQi, Xinxin Gao, Hua Fang, QiongGu, LingWang, LianquanGu. Syringic Acid Extracted from HerbadendrobiiPrevents Diabetic Cataract Pathogenesis by Inhibiting Aldose Reductase Activity.Evid. Based. Complement. Alternat. Med.2012. doi: 10.1155/2012/426537.

15. Wenxia Zhao, QiongGu, LingWang, Hu Ge, Jiabo Li and Jun Xu. Three-dimensionalPharmacophore Modeling of Liver-1 X Receptor Agonists, J. Chem. Inf.Model. 2011, 51, 2147-2155.

16. Yan Xin, Peng Ding, Liu Zhihong, Ling Wang, GuQiong, Xu Jun. BigData in Drug Design. Chin.Sci. Bull. 2015, 60: 558–565.

17. HangMa, Weixi Liu, Leslie Frost, LingWang, Liwen Kong, Joel A. Dain, Navindra P. Seeram. Thehydrolyzablegallotannin, penta-O-galloyl-β-D-glucopyranoside, inhibits theformation of advanced glycationendproducts by protecting protein structure.Mol. BioSyst. 2015, 11(5):1338-1347.
    
    

专利：

1.徐峻、王领、顾琼一种β-苯丙氨酸类化合物作为醛糖还原酶抑制剂的应用，中国专利号：ZL201110377528.7(已授权)

2. 董艺凝、王领、陈卫、徐峻、张灏、陈海琴一种耐热β-半乳糖苷酶突变体的构建，中国专利号：ZL2011101770088.8 (已授权)

3. 顾琼、曹影影、王领、徐峻、巫瑞波丹酚酸A用于制备防治老年痴呆症药物的应用，中国专利申请号：201310196330.8